[go: up one dir, main page]

BR9800524A - Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituìda na posição 8 - Google Patents

Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituìda na posição 8

Info

Publication number
BR9800524A
BR9800524A BR9800524-3A BR9800524A BR9800524A BR 9800524 A BR9800524 A BR 9800524A BR 9800524 A BR9800524 A BR 9800524A BR 9800524 A BR9800524 A BR 9800524A
Authority
BR
Brazil
Prior art keywords
lower alkyl
phenyl
hydrogen
triaza
decan
Prior art date
Application number
BR9800524-3A
Other languages
English (en)
Other versions
BR9800524B1 (pt
Inventor
Geo Adam
Andrea Cesura
Guido Galley
Francois Jenck
Frederick Monsma
Stephan Roever
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9800524A publication Critical patent/BR9800524A/pt
Publication of BR9800524B1 publication Critical patent/BR9800524B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)

Abstract

Patente de Invenção:<B>"DERIVADOS DE 1,4,3-TRIAZA-ESPIRO[4,5]DE-CAN-4-ONA SUBSTITUìDA NA POSIçãO 8"<D>. A presente invenção refere-se a compostos da fórmula: onde: R^ 1^ e R^ 2^ são, independentemente um do outro, hidrogênio, alquila inferior, alcóxi inferior ou halogênio; R^ 3^ é fenila, opcionalmente substituída por alquila inferior, CF~ 3~, alcóxi inferior ou halogênio; e R^ 4^ é hidrogênio, alquila inferior, alquenila inferior, -C(O)-alquila inferior, -C(O)-fenila, alquila inferior-C(O)-fenila, alquileno inferior-C(O)O-alquila inferior, alcanotriila-di-inferior-C(O)O-alquila inferior, hidróxi-alquila inferior, alquila inferior-O-alquila inferior, alquila inferior-CH(OH)CF~ 3~, fenila ou benzila, R^ 5^ e R^ 6^ são, independentemente um do outro, hidrogênio, fenila, alquila inferior ou di-alquila inferior ou podem formar conjuntamente um anel fenila, e R^ 5^ e um de R^ 1^ ou R^ 2^ podem formar conjuntamente um anel de 6 elementos saturado ou não-saturado, A é um anel saturado de 4 a 7 elementos, que pode conter um heteroátomo, tal como O ou S, e a sais de adição de ácido farmaceuticamente aceitáveis dos mesmos que são agonistas e/ou antagonistas do receptor OFQ.
BRPI9800524-3A 1997-01-30 1998-01-30 derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituÍda na posiÇço 8, medicamento que os contÉm, processo para preparaÇço dos mesmos, bem como seu uso. BR9800524B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97101409 1997-01-30
EP97119311 1997-11-05

Publications (2)

Publication Number Publication Date
BR9800524A true BR9800524A (pt) 2000-03-14
BR9800524B1 BR9800524B1 (pt) 2008-11-18

Family

ID=26145196

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9800524-3A BR9800524B1 (pt) 1997-01-30 1998-01-30 derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituÍda na posiÇço 8, medicamento que os contÉm, processo para preparaÇço dos mesmos, bem como seu uso.

Country Status (34)

Country Link
US (1) US6071925A (pt)
EP (1) EP0856514B1 (pt)
JP (1) JP3292457B2 (pt)
KR (1) KR100274107B1 (pt)
CN (1) CN1113881C (pt)
AR (1) AR011576A1 (pt)
AT (1) ATE202105T1 (pt)
AU (1) AU730147B2 (pt)
BR (1) BR9800524B1 (pt)
CA (1) CA2226058C (pt)
CO (1) CO4920223A1 (pt)
CZ (1) CZ27398A3 (pt)
DE (1) DE69800896T2 (pt)
DK (1) DK0856514T3 (pt)
EA (1) EA001357B1 (pt)
ES (1) ES2158622T3 (pt)
GR (1) GR3036523T3 (pt)
HR (1) HRP980043B1 (pt)
HU (1) HUP9800138A3 (pt)
ID (1) ID19773A (pt)
IL (1) IL123036A (pt)
MA (1) MA26470A1 (pt)
NO (1) NO310026B1 (pt)
NZ (1) NZ329627A (pt)
PE (1) PE59999A1 (pt)
PL (1) PL324571A1 (pt)
PT (1) PT856514E (pt)
SG (1) SG71077A1 (pt)
SI (1) SI0856514T1 (pt)
TR (1) TR199800085A3 (pt)
TW (1) TW457238B (pt)
UY (1) UY24865A1 (pt)
YU (1) YU2098A (pt)
ZA (1) ZA98570B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69803653T2 (de) * 1997-12-05 2002-08-29 F. Hoffmann-La Roche Ag, Basel 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
EP0921125B1 (en) * 1997-12-05 2002-01-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro[4,5]decan-4-on derivatives
US6166209A (en) * 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
US6277991B1 (en) 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
EP0963985B1 (en) 1998-06-12 2003-03-12 F. Hoffmann-La Roche Ag Di-or triaza-spiro(4,5)decane derivatives
PT963987E (pt) * 1998-06-12 2003-01-31 Hoffmann La Roche Spiro(piperidina-4,1'-pirrolo(3,4-c)pirrolo)
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
CO5150201A1 (es) * 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
DE69923744T2 (de) * 1998-10-23 2006-02-23 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten
AU1185300A (en) * 1998-11-20 2000-06-13 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
GB9900078D0 (en) * 1999-01-05 1999-02-24 Zeneca Ltd Chemical compounds
GB9914024D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
AU1382901A (en) * 1999-11-17 2001-05-30 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
CN1242993C (zh) * 2000-03-31 2006-02-22 日本新药株式会社 杂环衍生物和药物
MXPA03009239A (es) * 2001-04-10 2004-11-12 Johnson & Johnson Derivados de 1,3,8-triazapiro[4,5]decan-4-ona utiles para el tratamiento de trastornos mediados por el receptor orl-1.
EP1406629A1 (en) 2001-07-02 2004-04-14 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
EP1491212B1 (en) 2002-03-29 2012-08-08 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
EP1601674B1 (en) * 2002-09-09 2012-08-08 Janssen Pharmaceutica NV Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
ZA200510329B (en) * 2003-05-23 2007-04-25 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
US8067603B2 (en) 2003-09-25 2011-11-29 Solvay Pharmaceuticals B.V. Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
AU2007325355A1 (en) * 2006-11-28 2008-06-05 Janssen Pharmaceutica N.V. Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl) -1,3,8-triaza-spiro[4.5]decan-4-one
US8877779B2 (en) * 2007-03-01 2014-11-04 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
CN101679430B (zh) * 2007-04-09 2013-12-25 詹森药业有限公司 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物
TW201016675A (en) * 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
EP4455145A3 (en) * 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Piperidinyl nociceptin receptor compounds
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN106397225A (zh) * 2016-09-04 2017-02-15 王际菊 一种手性化合物的制备方法
CN106467476A (zh) * 2016-09-04 2017-03-01 王际菊 一种左旋胺基化合物的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US488082A (en) * 1892-12-13 Automatic gut-off for gas bxxenees
JPS5212171A (en) * 1975-07-17 1977-01-29 Yoshitomi Pharmaceut Ind Ltd Process for preparation of cyclohexane derivatives
US4076821A (en) * 1976-02-27 1978-02-28 Yoshitomi Pharmaceutical Industries, Ltd. 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof
US4160836A (en) * 1976-05-17 1979-07-10 Janssen Pharmaceutica N.V. Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
SU1095878A3 (ru) * 1980-10-22 1984-05-30 Жансен Фармасетика Н.В. (Фирма) Способ получени производных 1-(4-арилциклогексил)пиперидина или их фармацевтически пригодных солей или их стереоизомерных форм
US4374245A (en) * 1982-04-09 1983-02-15 Hoechst-Roussel Pharmaceuticals Inc. 8-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
JPS6012357B2 (ja) * 1984-01-23 1985-04-01 吉富製薬株式会社 脂環式誘導体
US4707484A (en) * 1986-11-25 1987-11-17 Hoffmann-La Roche Inc. Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
US5153225A (en) * 1986-12-10 1992-10-06 Bayer Aktiengesellschaft Substituted basic 2-aminotetralin in pharmaceuticals
DE3718317A1 (de) * 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
US5039804A (en) * 1989-12-13 1991-08-13 Glaxo Inc. Preparation of substituted alkali metal piperidine-4-carboxylates
DE4135473A1 (de) * 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
DE4405178A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Substituierte 1,3,8-Triaza-spiro(4,5)-decan-4-on-Derivate als Vorstufen zur Herstellung von Pharmazeutika

Also Published As

Publication number Publication date
JPH10212290A (ja) 1998-08-11
CN1191862A (zh) 1998-09-02
TR199800085A2 (xx) 1998-08-21
DE69800896D1 (de) 2001-07-19
CA2226058C (en) 2008-01-29
TR199800085A3 (tr) 1998-08-21
PT856514E (pt) 2001-10-31
HRP980043B1 (en) 2001-12-31
NO310026B1 (no) 2001-05-07
YU2098A (sh) 2001-03-07
HUP9800138A3 (en) 1999-03-01
NO980332D0 (no) 1998-01-26
EA001357B1 (ru) 2001-02-26
ID19773A (id) 1998-07-30
AR011576A1 (es) 2000-08-30
KR100274107B1 (ko) 2000-12-15
PE59999A1 (es) 1999-07-01
CN1113881C (zh) 2003-07-09
HUP9800138A2 (hu) 1998-09-28
DK0856514T3 (da) 2001-09-17
ATE202105T1 (de) 2001-06-15
ZA98570B (en) 1998-07-30
CA2226058A1 (en) 1998-07-30
TW457238B (en) 2001-10-01
IL123036A0 (en) 1998-09-24
GR3036523T3 (en) 2001-12-31
PL324571A1 (en) 1998-08-03
EP0856514B1 (en) 2001-06-13
NO980332L (no) 1998-07-31
IL123036A (en) 2000-12-06
CO4920223A1 (es) 2000-05-29
KR19980070900A (ko) 1998-10-26
AU730147B2 (en) 2001-03-01
CZ27398A3 (cs) 1998-08-12
EA199800108A1 (ru) 1998-10-29
SG71077A1 (en) 2000-03-21
HU9800138D0 (en) 1998-03-30
DE69800896T2 (de) 2002-03-28
ES2158622T3 (es) 2001-09-01
UY24865A1 (es) 2000-12-29
EP0856514A1 (en) 1998-08-05
SI0856514T1 (en) 2001-08-31
US6071925A (en) 2000-06-06
MA26470A1 (fr) 2004-12-20
JP3292457B2 (ja) 2002-06-17
AU5280998A (en) 1998-08-06
NZ329627A (en) 1999-11-29
BR9800524B1 (pt) 2008-11-18
HRP980043A2 (en) 1998-12-31

Similar Documents

Publication Publication Date Title
BR9800524A (pt) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituìda na posição 8
BRPI0714320A2 (pt) Derivado de imidazo[1,2-a] piridina-2-carboxamidas, sua preparação e sua aplicação em terapêutica
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
BR0209939A (pt) Composto ou seu sal, éster ou prodroga farmaceuticamente aceitável, formulação farmacêutica, uso do composto ou de seu sal, éster ou prodroga farmaceuticamente aceitável, e, método para tratar câncer
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
MY125414A (en) Aminopropylphosphinic acids
ES2182852T3 (es) Derivados de prolinamida.
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
BRPI0412291A (pt) antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
AU3850600A (en) Dalda analogs and their use
EA200000785A1 (ru) Новые сульфонамидные производные в качестве ингибиторов рассасывания костной ткани и ингибиторов адгезии клеток
BR9909253A (pt) Derivados de 2-ariletil-(piperidin-4-ilmetil) amina como antagonistas de receptor muscarìnico
IT1255802B (it) Derivati imidazolici ad attivita&#39; a ii antagonista
SE0102055D0 (sv) New Compounds
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
PT1001792E (pt) Utilizacao de compostos de sais e de complexos de vanadio aceites fisiologicamente
SE9904507D0 (sv) New compounds
WO2002000166A3 (en) New compounds useful as antibacterial agents
GR3034573T3 (en) Substituted benzyloxycarbonyl guanidines as Na+/H+ exchange inhibitors, process for their preparation, their use as medicinal or diagnostic agents as well as medicament containing them
ES2091126T3 (es) Nuevos compuestos biciclicos de pirimidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
BR0309080A (pt) Formulação de aerossol para a inalação, que contém um sal de tiotrópio

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/11/2008, OBSERVADAS AS CONDICOES LEGAIS.

B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 15A ANUIDADE(S), CONFORME ART. 87 DA LPI 9.279.

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.